Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support
Da. Rizzieri et al., Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support, J CL ONCOL, 17(10), 1999, pp. 3064-3074
Purpose: We performed a retrospective review to determine predictive and pr
ognostic factors in patients with metastatic breast cancer who received ind
uction therapy, and, if they responded to treatment, high-dose chemotherapy
,
Patients and Methods: Patients with metastatic breast cancer received induc
tion therapy with doxorubicin, fluorouracil, and methotrexate (AFM). Partia
l responders then received immediate high-dose chemotherapy, whereas those
who achieved complete remission were randomized to immediate or delayed hig
h-dose chemotherapy with hematopoietic stem-cell support, We performed a re
trospective review of data from these patients and used Cox proportional ha
zards regression models for analyses.
Results: The overall response rate for the 425 patients enrolled was 74% (9
5% confidence interval, 70% to 78%). Multivariate analysis of data from all
425 patients revealed that positive estrogen receptor status (P = .0041),
smaller metastatic foci (less than or equal to 2 v > 2 cm) (P = .0165), a l
onger disease-free interval from initial diagnosis to diagnosis of metastas
es (less than or equal to 2 v > 2 years) (P = .0051 ), and prior treatment
with tamoxifen (P = .0152) were good prognostic signs for overall survival.
Patients who had received prior adjuvant therapy (P = .0001) and those who
developed liver metastases (P = .0001) had decreased rang-term survival. I
n the subgroup of responders to AFM induction, multivariate analysis showed
that those with visceral metastases did less well (P = .0006), as did pati
ents who had received prior adjuvant therapy (P = .0023), However, those wh
o had received tamoxifen therapy in the adjuvant setting did better (P = .0
143).
Conclusion: The chance for long term remission with induction therapy with
AFM and high-dose chemotherapy is increased for hormone receptor positive-p
atients with nonvisceral metastases who have not received prior adjuvant ch
emotherapy and have long disease-free intervals, (C) 1999 by American Socie
ty of Clinical Oncology.